Quark Venture and GF Securities invest US$25 million in Microbion to advance a new class of drugs that combat antibiotic-resistant infections

Quark Venture and GF Securities announced a US$25 million investment in Microbion Corporation through its Global Health Sciences Venture Fund. The investment will enable Microbion to initiate and complete a Phase 1B/2A study in diabetic foot ulcer infections evaluating both safety and efficacy endpoints including eradication of infections and of biofilms. Quark Venture, a Vancouver-based health sciences venture capital company, is focused on equity financing of innovative biotechnology and health sciences companies with breakthrough technology platforms and projects. Microbion, a clinical stage biopharmaceutical company, is developing MBN-101 as the first product in a new class for the treatment of resistant and difficult to treat infections. Fasken Martineau was counsel to Quark Venture with a team led by Roger Kuypers that included Jon Conlin and Jasmin Zeng.